The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is one of the first controlled studies on Manuka honey for dry mouth, so the finding is intriguing but far from settled — especially since it was single-blind and tested only in a clinical elderly population.
This is early evidence, and the effect is specific to people living with HIV — so it doesn't yet tell you anything about Moringa for healthy individuals.
This is one of the first studies on this specific strain-antibiotic pairing, so the subgroup finding is exploratory and needs replication before drawing firm conclusions.
This large effect comes from a single small trial in Thai children, so while promising, it needs replication before generalizing.
This is an early, intriguing signal that L-carnitine may help with fertility in PCOS, but the tiny sample size and lack of blinding mean the finding is far from settled — and chemical pregnancy is an early milestone, not a guarantee of a live birth.
This is among the first reviews to flag a specific benefit of probiotics for gum health in pediatric dentistry, but with little prior data on this pairing and no specified dose, it's a promising clue — not a settled recommendation.
This is among the first controlled trials to show grape seed extract can meaningfully improve a physical measure of vein function in people with varicose veins, but because both researchers and participants knew who was getting the supplement, the placebo effect and observer bias can't be ruled out.
This systematic review of 491 patients adds early evidence that correcting a vitamin D deficiency might help tame chronic urticaria, but the findings come from studies that weren't blinded, and the body of evidence is still too thin to recommend high-dose vitamin D for everyone with hives.
This is one of the first meta-analyses to look at this specific probiotic strain in this fragile population, so the result is intriguing but far from settled — the low-quality evidence means the true benefit could be smaller or even absent.
This is one of the first studies to examine probiotics pretreatment, so the result is a signal, not a sure thing — expect more data before acting on it.
This is an early look at whey protein as a supportive aid during cancer treatment, not a settled finding — and the review itself emphasizes the need for stronger studies before drawing firm conclusions.
This is one of the first systematic reviews to single out L-carnitine as the top performer for progressive sperm motility with a remarkably large effect size, but the finding is based on a narrow clinical population and the dose used wasn't specified — so it's a promising signal, not a settled recommendation.
This is among the first controlled trials for this specific probiotic strain on blood sugar, and while the result is statistically robust, the benefit has only been shown in people with type 2 diabetes who are also taking standard hypoglycemic drugs.
This is among the first meta-analyses to look at cocoa specifically for triglycerides in type 2 diabetes, so the finding is intriguing but far from settled — the low certainty and high inconsistency between studies mean you shouldn't change your supplement habits based on this alone.
This is one of the first systematic analyses of thistle for kidney function, and its null finding directly challenges popular claims — but the picture is now contested, not settled, because the same review found a benefit in a specific clinical scenario (drug-induced acute kidney injury) that doesn't apply to most supplement users.
This is among the first solid evidence linking probiotics to bone density, so the finding is promising but far from conclusive — much larger trials are needed to know if the effect is real and meaningful.
This suggests yacon root may help with weight control, but because the underlying studies had notable limitations and this is one of the first meta-analyses on the topic, the effect should be viewed as promising, not proven.
This small, double-blind trial suggests astaxanthin can meaningfully boost antioxidant defenses in people with chronic heart failure, but because it's among the first studies on this pairing, the results need replication before they apply broadly.
This umbrella review adds to early hints that folic acid might protect against autism, but because it's among the first indexed studies on this pairing and the evidence is low quality, the finding should be treated as preliminary, not definitive.
This is an early, small signal that *L. reuteri* might improve blood sugar control in a specific clinical population, but the lack of effect on the gum disease it was supposed to treat means the metabolic benefit is a side finding, not a proven standalone effect.
This is an early signal that vitamin C might help stabilize blood pressure in septic shock, but the evidence is too thin to generalize beyond the ICU setting.
This is the first RCT to show Bifidobacterium longum can shift a key hormone-binding protein in PCOS, but the lack of symptom improvement means the clinical relevance is still uncertain — and the effect may not apply outside this specific patient group.
This is one of the first broad reviews to suggest curcumin helps wounds heal, but with only 19 trials and no standardized dosing, it's a promising early signal—not a settled prescription.
This finding comes from a single RCT within a small systematic review of 11 trials, so it's far from conclusive; the review itself says the evidence is insufficient for strong recommendations.
This is among the first systematic reviews on Rhodiola for stress; while the results are consistently positive, the evidence is still preliminary and not strong enough for firm recommendations.
This is an early, intriguing signal that a common vegetable extract might help cancer patients live longer when added to standard chemotherapy, but the low-quality evidence means we can't rely on it until larger, properly controlled trials confirm the finding.
This suggests peanut butter may help with a specific functional task (rising from a chair) in fall-prone older adults, but because the study wasn't blinded and is among the first of its kind, the finding needs replication before you'd change your snack habits based on it.
This is an unusually large effect for a common, painful side effect of head-and-neck cancer treatment, but it's the first controlled trial on this pairing, so the result needs replication before you can bank on it.
This is the first strong hint that vitamin C might improve lung function in children through epigenetic changes, but with only 4 prior studies on the pairing and mixed results overall, we are far from a general recommendation — the finding needs replication.
This small, year-long clinical trial in allergic children suggests that a much lower maintenance dose might work just as well as the typical higher one, but because this is among the first studies to test that comparison, the finding needs replication before it changes practice.